Connecticut Bill Would Require Buprenorphine in Emergency Departments

A proposed Connecticut law could expand access to buprenorphine and other forms of medication assisted treatment at one of the most critical moments in the addiction cycle, the emergency room visit.

Senate Bill 365, currently under legislative review, would require emergency departments statewide to offer buprenorphine to patients presenting with opioid use disorder, a move addiction medicine specialists say is long overdue.

Why Medication-Assisted Treatment Belongs in the ER

For people struggling with opioid dependence, the emergency department is often the first, and sometimes only, point of contact with the healthcare system.

Yet despite overwhelming evidence supporting medication-assisted treatment, many ER physicians have historically declined to initiate it, frequently due to misconceptions about opioid use disorder as a medical condition.

Dr. Cara Borelli, an emergency medicine and addiction medicine physician working in New Haven, argues that this gap costs lives.

Writing in support of SB 365, she draws a stark comparison: an ER doctor would never refuse to treat a heart attack, yet patients actively requesting buprenorphine for opioid use disorder are routinely turned away.

Research backs her up, one study found that patients who received naloxone (the overdose-reversal medication) had a one-year mortality rate exceeding that of people who experienced a life-threatening heart attack.

What Buprenorphine Does and Why It Matters for Opioid Detox

Buprenorphine is a partial opioid agonist, it binds to the same receptors as opioids like heroin or fentanyl, but activates them only partially.

This makes it highly effective for managing opioid withdrawal symptoms and cravings without producing a significant high, dramatically lowering the risk of relapse and overdose.

It is a cornerstone of evidence-based medical detox for opioid use disorder and is often dispensed as Suboxone, a combination of buprenorphine and naloxone.

A landmark 2020 study published in JAMA found that patients treated with buprenorphine or methadone had a 76% lower risk of overdose at three months compared to those who went untreated.

A Yale-affiliated Connecticut study reinforced these findings with sobering data: treating opioid use disorder without these medications was associated with a 77% higher risk of fatal overdose than receiving no treatment at all.

Methadone as an Alternative MAT Option

SB 365 may also be amended to include methadone as an acceptable form of medication-assisted treatment to satisfy the bill’s requirements.

Methadone, like buprenorphine, treats opioid withdrawal, reduces cravings, and has decades of clinical research supporting its effectiveness.

It is typically dispensed through federally regulated opioid treatment programs (OTPs) rather than general prescriptions, a logistical difference that would need to be addressed for ER settings.

Dr. Borelli supports including methadone as an option, provided clinicians assess each patient’s individual safety profile before prescribing.

The Financial Case for ER-Based MAT

Opponents of SB 365, including the Connecticut Hospital Association, have characterized the bill as an unfunded mandate. Dr. Borelli and the clinical data tell a different story.

Patients receiving buprenorphine or methadone saw a 32% reduction in opioid-related emergency department visits in the same 2020 JAMA study.

Insurance data shows patients prescribed buprenorphine incur over $20,000 less in annual healthcare costs than those who go untreated, a substantial Medicaid savings for Connecticut taxpayers.

The downstream medical costs of untreated opioid use disorder are severe. Dr. Borelli has witnessed patients denied bridge prescriptions in the ER go on to develop endocarditis (heart infections averaging nearly $200,000 to treat, often requiring open-heart surgery), kidney failure necessitating dialysis, spinal infections causing paralysis, and brain injuries requiring lifelong care.

Bridge Prescriptions and Follow-Up Care

SB 365 includes a provision requiring that patients initiated on buprenorphine in the ER receive a bridge prescription lasting until their follow-up appointment.

Dr. Borelli advocates for strengthening this provision to mandate a minimum 7-day supply, noting that follow-up can occur across a range of settings, with addiction providers, psychiatrists, primary care physicians, or via telehealth.

This continuity of care is essential. Medical detox is most effective when it connects patients to ongoing treatment, not just an acute intervention.

Finding Buprenorphine and Detox in Connecticut

If you or someone you love is dependent on opioids, alcohol, or benzodiazepines, medically supervised detox programs are the safest path to beginning recovery. Search detox.com’s directory of detox centers or call 800-996-6135(Sponsored) to get started with treatment today.